PDGFRA and osteosarcoma: PDGFRA was overexpressed in 22.1% of the sarcomas, including, 38.5% of angiosarcoma, 33.3% of liposarcoma, 33.3% of fibrosarcoma, 31.8% of Ewing's sarcoma, 30.8% of chondrosarcoma, 27.8% of osteosarcoma, 27.8% of UPS and 18.3% of non-uterine LMS.